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Background: To investigate the effect of prostaglandin depletion by means of COX-inhibition on cholinergic
enhanced spontaneous contractions.
Methods: The urethra and bladder of 9 male guinea pigs (weight 270–300 g) were removed and placed in an
organ bath with Krebs’ solution. A catheter was passed through the urethra through which the intravesical pressure
was measured. The muscarinic agonist arecaidine, the non-selective COX inhibitor indomethacin, and PGE2 were
subsequently added to the organ bath. The initial average frequency and amplitude of spontaneous contractions in
the first 2 minutes after arecaidine application were labelled Fini and Pini, respectively. The steady state frequency
(Fsteady) and amplitude (Psteady) were defined as the average frequency and amplitude during the 5 minutes before
the next wash out.
Results: Application of 1 μM PGE2 increased the amplitude of spontaneous contractions without affecting
frequency. 10 μM of indomethacin reduced amplitude but not frequency.
The addition of indomethacin did not alter Fini after the first application (p = 0.7665). However, after the second
wash, Fini was decreased (p = 0.0005). Fsteady, Psteady and Pini were not significantly different in any of the conditions.
These effects of indomethacin were reversible by PGE2 addition..
Conclusions: Blocking PG synthesis decreased the cholinergically stimulated autonomous contractions in the
isolated bladder. This suggests that PG could modify normal cholinergically evoked response. A combination of
drugs inhibiting muscarinic receptors and PG function or production can then become an interesting focus of
research on a treatment for overactive bladder syndrome.Background
The overactive bladder syndrome (OAB) is defined as
urinary urgency with or without urgency incontinence,
urinary frequency and nocturia. These symptoms still
present a therapeutic challenge. Currently, antimuscari-
nic drugs are first-line treatment for OAB. How their
beneficial action is achieved is still a matter of discus-
sion. Depending on the studied compound, antimus-
carinic drugs often have only moderate response rates* Correspondence: sajjad_r@yahoo.com
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distribution, and reproduction in any mediumwhen compared to placebo [1]. However, adverse effects
and decreasing efficacy cause long-term compliance
problems [2]. Therefore, it is desirable that alternative
treatment methods are developed and made available.
The lower urinary tract has two basic functions: to
store urine for most of the time at low pressure and
expel it at a socially convenient time and place. There-
fore, it is equipped with an extensive relay network to
transmit information on bladder fullness to the brain
[3]. One of the proposed mechano-transduction
mechanisms is stretch dependent urothelial release of
mediators such as acetylcholine, Nitric oxide, ATP and
Prostaglandins (PG) [4]. PGE2 appears to be the main
PG involved in the regulation of the bladder [5] and
exert its effect through the endoprostanoid receptors, oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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described [6,7]. In the bladder, PG release depends on
de novo synthesis rather than release from pre-formed
stores [8]. Cyclooxygenase type 1 and 2 (COX-1 and
COX-2) are the central enzymes in the production of PG
[9]. COX-1 is a constitutive form, whereas COX-2 an in-
ducible form in the bladder. Its expression is regulated by
various stimuli, including pro-inflammatory cytokines and
growth factors [9]. An increased expression of COX-2 has
been described immediately after experimentally induced
bladder outlet obstruction [10]. There is an increasing
amount of data available pointing to a role of PG in the
regulation of non-voiding contractions and afferent acti-
vity [10-13]. The isolated whole bladder shows autono-
mous small contractions, which resemble non-voiding
contractions that increase in amplitude and/or frequency
by muscarinic agonists [14,15] and PG [10]. Similarly,
intravesical PG administration in vivo increases non-
voiding contractions during bladder filling and decreases
the inter-micturition interval, [16] whereas EP1 and EP3
knockout mice show an increased micturition threshold.
Moreover, in these animals, the PGE2 induced hyperacti-
vity is decreased [16]. How PG exerts its effect is not well
understood. However, involvement of capsaicin sensitive
afferents and autonomous ganglia has been suggested
[12]. An interaction or crosslink between the cholinergic
and prostanoid pathway has been suggested before [17]
and may be another mechanism of action. This idea is
supported by the fact that muscarinic agonists can induce
production of PGE2 [18].
The current study aims to further investigate the
crosslink between the cholinergic and prostanoid path-
way in order to explore a possible new treatment mo-
dality through COX inhibition for OAB. Therefore, the
non-specific COX inhibitor indomethacin was used to
investigate the effect of prostaglandin depletion on cho-
linergic enhanced spontaneous contractions.
Methods
Animals
A total of 9 male guinea pigs (weight 270–300 g) were
killed by cervical dislocation, followed by exsanguination.
Male guinea pigs were used because of the favourable ur-
ethral length, which made catheterization of the isolated
bladder easier. All procedures were carried out with the ap-
proval of guidelines of the animal ethics committee of the
University of Maastricht and were in line with European
Community guidelines.
Pressure recordings
The urinary bladder and proximal urethra were excised
immediately after cervical dislocation of the animal and
placed in Krebs’ solution (mM: NaCl 121.1; KCl 1.87;
CaCl2 1.2; MgSO4 1.15; NaHCO3 25; KH2PO4 1.17;glucose 11.0), bubbled with 5% CO2 and 95% O2 (pH 7.4,
34°C). The urethra was cannulated with a flexible plastic
cannula (2 mm diameter) secured using a fine ligature.
The bladder was then transferred to a heated organ bath
(40 mL, 33–36°C) containing constantly gassed Krebs’ so-
lution, and the cannula was connected through a fluid-
filled tube containing three-way connector to a pressure
transducer (DTX Plus, Becton Dickinson, Franklin Lakes,
NJ, USA). The bladder was allowed to empty. Subse-
quently, the bladder was filled to 2 ml in approximately
30 seconds. The transducer output was amplified, digitized
at 20 Hz and recorded using a data capture system
(MP100 with AcqKnowledge 3.7.3 software, BIOPAC sys-
tems inc, California). The pressure range of this apparatus
was 0.02–180 cmH2O. The transducer was calibrated be-
fore each experiment. Recordings started 30 minutes after
the animal was sacrificed.
The timeline of the experiments is given in Figure 1.
The pressure recordings started with cholinergic stimu-
lation with 1 μM of the cholinergic agonist, arecaidine
(t = 0). This was followed by empting the organ bath and
washing the bladder twice with fresh Krebs’ solution,
15 minutes after arecaidine stimulation (t = 15). In order
to investigate the effect of inhibition of PG production
on the arecaidine response, the non-selective COX in-
hibitor, indomethacin was applied to the bladder For this
purpose, after another 15 minutes, 10 μM of the non-
specific COX inhibitor indomethacin was added to the
Krebs’ solution in the organ bath (t = 30), followed by a
second stimulation with 1 μM arecaidine, given 15 min-
utes later (t = 45). After another 15 minutes, a wash step
was conducted (t = 60). This was then followed by an
arecaidine stimulation (t = 75), followed by a wash step,
15 minutes later (t = 90). At this point, in 4 experiments,
1 μM PGE2 was added to the organ bath after 10 minutes
in order to check the reversibility of the indomethacin
effect by PGE2. (t = 105). Again this was followed by are-
caidine stimulation 30 minutes later (t = 135). At the end
another wash step was conducted (t = 150).
Drugs
Concentrated drug solutions were added directly to the
bath to achieve the required final dilution. All drugs were
added to the solution bathing the serosal surface. The
non selective COX inhibitor, indomethacin (Sigma, St
Louis, Missouri) was used in a concentration of 10 μM.
As muscarinic agonist, a 1 μM concentration of arecai-
dine but-2-ynyl ester tosylate (Tocris, Avonmouth, UK)
was used [14]. PGE2 (Sigma, St Louis, Missouri) was used
in a concentration of 1 μM [19].
Definitions
In Figure 2 the different defined phases of the bladder
contraction amplitude and frequency are marked. The
Figure 1 The timeline of the experiments. Pressure recordings started with stimulation of the guinea pig bladder by adding the cholinergic
agonist arecaidine to the organ bath with Krebs’ solution in which the isolated guinea pig bladder was kept. After 15 minutes the Krebs’ solution
is renewed (wash step). The COX inhibitor indomethacin was added 15 minutes after the first wash step. This was then followed by two sets of
arecaidine stimulation and wash steps each separated by 15 minutes. In four experiments PGE2 was added to the organ 15 minutes after the
third wash step which was then followed by a set of arecaidine stimulation and wash step, 30 minutes later.
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line contractions before arecaidine stimulation. The ini-
tial phase (ini) is defined as the first 2 minutes after
arecaidine application and is characterized by average
frequency (Fini) and amplitude (Pini) of spontaneous con-
tractions.The steady state (steady) is defined as the
5 minutes before the next wash out, and is characterized
by frequency (Fsteady) and amplitude (Psteady).
Instantaneous frequency plot
The raw pressure at the peak of every contraction was
acquired from the measurement system along with the
exact time of the contractions. The frequencies were then
calculated and plotted as demonstrated in the figures.
Statistical analysis
The analysis of the data was done, by conducting a
double sided, paired t-test using the SPSS software.
Results
The figures displayed represent raw experimental data
conducted in different animals on different days.
Response to muscarinic stimulation
The isolated bladder response to the non-selective mus-
carinic agonist, arecaidine, is shown in Figure 2 (arrow).
The initial phase was characterized by a rapid rise in basal
pressure, followed by high-frequency bladder contractions.
Frequency declined within 5 minutes after which contrac-
tion amplitude increased, eventually reaching a steady
state. These findings are consistent with previous observa-
tions [15,20].
Effect of prostaglandin and COX inhibition on the
baseline activity
The effects of PGE2 and indomethacin on the baseline
transients are shown in Figure 3. Pbase increased about
2-fold in the presence of 1 μM PGE2 (control 8.0 ± 4.6
cmH2O vs. PGE2 17.1 ± 7.5 cmH2O; p = 0.01; n = 5).Fbase was not affected by PGE2 (control 0.026 ± 0.01 Hz
vs. PGE2 0.039 ± 0.02 Hz; p = 0.26; n = 5).
Application of 10 μM of indomethacin decreased Pbase
(control 13.2 ± 6.2 cmH2O vs. indomethacin 11.6 ± 5.9
cmH2O; p = 0.03; n = 6). Fbase was not affected by indo-
methacin (control 0.028 ± 0.0066 Hz vs. indomethacin
0.030 ± 0.0051 Hz; p = 0.32; n = 6).
Effect of indomethacin and PGE2 on the muscarinic
response
The recordings of an experiment with COX inhibitor indo-
methacin are shown in Figure 4. At t = 30 indomethacin
was added to the bath. The bladder response on arecaidine
stimulation in the presence of indomethacin (t = 45) was
not different from the response to arecaidine stimulation in
the absence of indomethacin (t = 0), for any of the para-
meters Pini (p = 0.081), Fini (p = 0.77), Psteady (p = 0.19),
F steady (p = 0.32).
However, after a wash step and a the second stimula-
tion, with arecaidine (t = 75), Fini was significantly
decreased (p = 0.0005), whereas Pini (p = 0.086), Fsteady
(P = 0.32) and Psteady (p = 0.33) remained unchanged.
To check the reversibility of the described indometh-
acin effect after the wash step, by prostaglandin, PGE2
was given exogenously at t = 105 in four animals. One of
these recordings is shown in Figure 5.
After adding PGE2 a strong response, i.e. high ampli-
tude contractions, were observed as shown in Figure 5.
In order to achieve a steady state before adding arecai-
dine, arecaidine was added 30 minutes later instead of
15 minutes.
Data of all four experiments show that, compared to
arecaidine stimulation after indomethacin exposure (t = 45
and T = 75), Fini was increased (p = 0.014), so the indo-
methacin effect on Fini was reversed by PGE2. There were
no changes noted in Pini (0.38), neither Fsteady (0.27) nor
Psteady (0.19). Fini at t = 135 was not significantly changed
when compared to the initial arecaidine stimulation (t = 0)
(p = 0.06).
Figure 2 Pressure changes and instantaneous frequency plot of an isolated guinea pig bladder induced by arecaidine. A. Pressure
changes of an isolated guinea pig bladder induced by 1 μM arecaidine. The average frequency in the initial phase, defined as the first 2 minutes
after arecaidine application, is labelled Fini. The steady state frequency (Fsteady) is defined as the average frequency over a 5 minutes period prior
to the wash out. B. Instantaneous frequency plot of an isolated guinea pig bladder. The time of stimulation with 1 μM arecaidine is indicated
with an arrow. The frequency of the autonomous contractions initially increases and then return back to a lower steady level after
approximately 5 minutes.
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Presence of PG receptors in the bladder and involve-
ment of PG in the bladder physiology has been demon-
strated before [6,13,21,22]. The urothelium is shown to
release acetylcholine, ATP, Nitric Oxide and prostaglan-
din [4,6]. The physiological role of these signals is poorly
understood and a possible interaction between them has
not widely been considered.
The link between PG and cholinergic effects in the blad-
der has been suggested before. In a study in rat detrusor it
was shown that indomethacin suppressed frequency of
muscarinic-induced contractions but only in strips of
certain orientation and with urothelium intact [23].Furthermore, in another study in rat bladders studied in
an organ bath model it was shown that PGE2 release could
be antagonized by indomethacin and concluded that COX
inhibitors suppress ATP release from bladder epithelium
via decreasing PGE2. In addition, EP1 and/or EP3 recep-
tors were suggested to participate in this effect [24]. In a
study in rabbit detrusor strips it was shown that both
indomethacin and ibuprofen suppress spontaneous
contractions [25]. In addition, it has been suggested that
endogenous PGs in isolated human detrusor facilitate the
action of acetylcholine [17]. This effect was thought to be
through an increase in the concentration of the choliner-
gic neurotransmitter probably via an inhibition of the
Figure 3 Spontaneous activity of the isolated guinea pig bladder after administration of PGE2 and indomethacin. A. Spontaneous
activity of the isolated guinea pig bladder. The arrow indicates when 1 μM of PGE2 is added. The amplitude of the contractions is significantly
increased. B. Spontaneous activity of the isolated guinea pig bladder. The arrow indicates when 10 μM indomethacin is added. The amplitude of
the contractions is slightly decreased by indomethacin. However, the frequency of contractions is not affected.
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suggested to have a modulatory role in the release of
acetylcholine and ATP in the guinea pig bladder [26].
The aim of our study was to further investigate the
link between the prostaglandin and the cholinergic sys-
tem and explore the possibility of COX inhibition as a
treatment modality for OAB. It has been demonstrated
that that there is a basal acetylcholine release in human
detrusor muscle in vitro [27]. This release was resistant
to nerve blocker tetrodotoxin, and considerably reduced
when the urothelium was removed, suggesting that the
released acetylcholine was of non-neuronal origin and,
at least partly, generated by the urothelium. Stretch of
the muscle increased the release. There are thus reasons
to believe that acetylcholine can be generated by non-
neuronal structures within the bladder, and it may be
speculated that urothelially derived acetylcholine can
excite suburothelial afferent nerves and that this contri-
butes to OAB. During filling of the bladder, there is no
activity in the parasympathetic nerves innervating the
bladder, and direct evidence for spontaneous release of
acetylcholine from nerves during the filling phase of the
bladder has so far been lacking [28]. However, it has
been shown that there is a spontaneous tetrodotoxin-
resistant release of acetylcholine from autonomic cholin-
ergic nerves in guinea pig and rat bladders under both
in vitro and in vivo conditions [29]. This release was
shown to significantly affect bladder contractility (au-
tonomous activity) [29]. These findings provide furthersupport for the hypothesis that antimuscarinic drugs can
act also by inhibiting a myogenic afferent pathway dur-
ing the filling phase [28]. Thus, during the storage phase,
acetylcholine may be released from both neuronal and
non-neuronal sources, and directly or indirectly excite
afferent nerves suburothelially and within the detrusor.
It is has been shown that an isolated bladder in an
organ bath shows spontaneous rhythmical contractions
[14,15]. The frequency of this baseline activity was
shown to be unaffected by PGE2. and the COX-inhibitor
indomethacin (Figure 3). Although Fbase was not signifi-
cantly affected by PGE2 (control 0.026 ± 0.01 Hz vs.
PGE2 0.039 ± 0.02 Hz; p = 0.26; n = 5) there was an in-
crease of about 50%. Therefore, this might be due to a
lack of power in our study and might become significant
if more animals were tested. On the other hand, the
amplitude of the baseline contractions was significantly
raised by PGE2 and decreased by indomethacin, indicat-
ing that PG is needed for and has a stimulating effect on
the amplitude of these baseline contractions.
The non-selective muscarinic agonist, arecaidine induces
a rapid rise in basal pressure with high-frequency bladder
contractions which declined within 5 minutes. After this,
contraction amplitude increased, eventually reaching a
steady state. These findings are consistent with previous
observations [15,20] and represent a typical response by
the isolated bladder to arecaidine as shown in Figure 2.
Furthermore, data presented in this paper show that
inhibition of PG production by indomethacin diminished
Figure 4 Timeline, pressure changes and instantaneous frequency plot of an isolated guinea pig bladder pre-exposed to indomethacin
before stimulation with arecaidine. A. an outline of the experiment. After the first 1 μM arecaidine simulation (enlarged in panel B as 1), the
organ bath is washed to remove the arecaidine. After 15 minutes, 10 μM indomethacin is added followed by a second stimulation of arecaidine
(enlarged in panel B as 2). After a wash step, a third arecaidine stimulation is performed (enlarged in panel B as 3). B. Parts of panel A in an
expanded scale. C. Instantaneous frequency plot comparing the three conditions described in panel A.
Rahnama’i et al. BMC Urology 2013, 13:8 Page 6 of 9
http://www.biomedcentral.com/1471-2490/13/8the average frequency of the initial burst of transients of
the isolated guinea pig bladder, in the first 2 minutes
after of the application of the muscarinic agonist, arecai-
dine (Fini).
As explained in Figure 2B, indomethacin by itself, i.e.
in the absence of arecaidine, did not change baseline
contraction frequency but slightly reduced contraction
baseline amplitude. However, arecaidine stimulation
after COX inhibition by indomethacin application, lead
to a significantly less outspoken response, after the
second arecaidine stimulation. The explanation of this
delayed effect of indomethacin on Fini could simply be
due to a longer incubation time needed for indometh-
acin to exert its effect. Indomethacin is still believed to
be present in the organ bath since the recordings after
the second wash step are not the same as control. This
can be clearly seen in Figures 4 and 5, especially at the
diagram at the bottom of the figures. The difference in 1
(control) and 3 (after second wash step) is only in the
addition of indomethacin and since these two recordings
are persistently different in all experiments we assume
that indomethacin is still present in the system.Furthermore, the conducted control experiments (data
not included) have ruled out that this effect is simply
due to time or a repeated wash step.
However, another plausible explanation may be that
the second wash step, applied after the second arecai-
dine stimulation, could have caused a further washout of
the previously produced PG. Since de novo production
of the PG is inhibited by indomethacin, there is no new
PG production in the isolated bladder. The delayed
effect may therefore also be explained by the small
amount of previously produced PG, which might still be
present and active in the system during the first arecai-
dine stimulation. Therefore, the initial burst induced by
arecaidine is not affected the first time. We hypothesize
that after the addition of indomethacin followed by the
second wash step, there is practically no PG left in the
organ bath and the tissue. Therefore, there is a signifi-
cantly less outspoken response to arecaidine.
Thus, inhibition of PG production seems to reduce Fini
of the muscarinic response and it can be suggested that
PG is necessary for the normal increase in autonomous ac-
tivity following cholinergic stimulation, i.e. the arecaidine
Figure 5 Timeline, pressure changes and instantaneous frequency plot of an isolated guinea pig bladder after stimulation with
arecaidine showing the reversibility of the indomethacin effect by PGE2. A. an outline of another typical experiment. The same protocol as
described in Figure 3 was followed. To check the reversibility, at the end of the experiment, 1 μM PGE2 is added in to the organ bath and a last
arecaidine stimulation is conducted. The first arecaidine stimulation is marked as (1) followed by the stimulation with presence of indomethacin
(2) followed by stimulation after a wash step (3). At the end an arecaidine stimulation is shown after adding PGE2 to the system (4). B. Each of
the arecaidine responses shown in panel A in an enlarged scale, starting from the left, the first trace shows the basic arecaidine response (1), the
second trace shows the previously shown effect of the inhibition of PG production (2). The third trace shows the effect of washing the organ
bath with fresh Krebs’ before stimulation with arecaidine (3). The last trace from the right shows the effect of addition of exogenous PGE2 (4).
C. Instantaneous frequency plot comparing the four conditions described in panel A.
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increases the initial burst frequency after arecaidine stimu-
lation, to levels even higher than the control (Figure 4).
PG has been suggested to be linked to acetylcholine
before. In a study conducted in another species and an-
other organ system, namely the mouse mesenteric ar-
tery, it has been shown that acetylcholine hyperpolarises
the smooth muscle cell membrane with two kinetic
components, one which is indomethacin-sensitive and
the other which is indomethacin-insensitive [30]. The
indomethacin-sensitive component is suggested to be
linked to prostanoids [30]. Thus, PG was suggested to
have a role in this muscarinic response of these arterial
smooth muscle cells, which is confirmed by our experi-
ments. Moreover, it is known that in the guinea pig
bladder, ATP can activate PGE2 production by a com-
plex mechanism involving the purinergic receptors P2Xand P2Y [13]. This ATP response was shown to be
inhibited by the COX inhibitor indomethacin [13]. This
suggests a complex mechanism of cholinergic receptor
mediated, ATP induced, stimulation of COX enzyme
resulting in an increased PG production.
Another clue for a link between PG and the muscarinic
system comes from clinical data. It is known that inhi-
bition of cholinergic activity in the bladder by antimuscari-
nic drugs, although effective in reducing the symptoms of
urgency and frequency, does not have a high enough
dosage to target the muscle cells [31,32]. Therefore, the
suggestion is made that anticholinergic drugs could target
the mechanisms operating during the filling phase [33-35]
through locally produced substances such as ATP, NO
and PG [10,36].
Drake et al. reported increased bladder sensation to be
associated with localized contractile activity in the bladder
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motions are significantly more prevalent in patients with
urgency than in asymptomatic volunteers [37]. In other
words, urgency is suggested to be associated with autono-
mous activity of the detrusor and altered micro-motions.
It has been shown that patients with the overactive
bladder syndrome (OAB) have an increased urinary PG
[38,39] which is thought to affect bladder activity di-
rectly by effects on smooth muscle and/or indirectly via
effects on neurotransmission [40].
Conclusions
In summary, our data show that inhibition of PG produc-
tion has an influence on the cholinergically induced blad-
der response in the isolated bladder. In order to evaluate
the effect of PG on the autonomous activity in the pre-
sence of local reflex loops and control by the central ner-
vous system, these experiments should be performed
in vivo. By this, a combination of drugs inhibiting both
muscarinic receptors and PG function or production can
become an interesting focus of research in the quest for a
better treatment for OAB. In order to gain a full under-
standing of the PG effect shown on the cholinergically
induced bladder response, more studies need to be con-
ducted using selective EP blockers in vitro and in vivo.
Competing interest
The authors declare that they have no competing interests.
Authors’ contribution
MSR carried out the experiments, analysed the data and drafted the
manuscript. GVK helpt with the study design. SdW supervised the analysis of
the data. GvK, SdW and PvK supervised the drafting of the manuscript. All
authors read and approved the final manuscript.
Received: 15 November 2012 Accepted: 1 February 2013
Published: 7 February 2013
References
1. Michel MC, de la Rosette JJ: Role of muscarinic receptor antagonists in
urgency and nocturia. BJU Int 2005, 96(Suppl 1):37–42.
2. Andersson KE: Drugs and future candidates. Can Urol Assoc J 2011,
5(5 Suppl 2):S131–S133.
3. Griffiths D, Tadic SD: Bladder control, urgency, and urge incontinence:
evidence from functional brain imaging. Neurourol Urodyn 2008, 27(6):466–474.
4. Birder L: Role of the urothelium in bladder function. Scand J Urol Nephrol
2004, 215:48–53.
5. Pinna C, Zanardo R, Puglisi L: Prostaglandin-release impairment in the
bladder epithelium of streptozotocin-induced diabetic rats. Eur J
Pharmacol 2000, 388(3):267–273.
6. Rahnama’i MS, van Kerrebroeck PE, de Wachter SG, van Koeveringe GA: The role
of prostanoids in urinary bladder physiology. Nat Rev Urol 2012, 9(5):283–290.
7. Narumiya S, Sugimoto Y, Ushikubi F: Prostanoid receptors: structures,
properties, and functions. Physiol Rev 1999, 79(4):1193–1226.
8. Piper P, Vane J: The release of prostaglandins from lung and other
tissues. Ann N Y Acad Sci 1971, 180:363–385.
9. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev
Pharmacol Toxicol 1998, 38:97–120.
10. de Jongh R, van Koeveringe GA, van Kerrebroeck PE, Markerink-van Ittersum
M, de Vente J, Gillespie JI: The effects of exogenous prostaglandins and
the identification of constitutive cyclooxygenase I and II
immunoreactivity in the normal guinea pig bladder. BJU Int 2007,
100(2):419–429.11. Maggi CA: Prostanoids as local modulators of reflex micturition.
Pharmacol Res 1992, 25(1):13–20.
12. Maggi CA, Giuliani S, Conte B, Furio M, Santicioli P, Meli P, Gragnani
L, Meli A: Prostanoids modulate reflex micturition by acting
through capsaicin-sensitive afferents. Eur J Pharmacol 1988,
145(2):105–112.
13. Nile CJ, de Vente J, Gillespie JI: Stretch independent regulation of
prostaglandin E(2) production within the isolated guinea-pig lamina
propria. BJU Int 2009, 105(4):540–8.
14. Gillespie JI, Harvey IJ, Drake MJ: Agonist- and nerve-induced phasic
activity in the isolated whole bladder of the guinea pig: evidence
for two types of bladder activity. Exp Physiol 2003, 88(3):343–357.
15. Finney SM, Stewart LH, Gillespie JI: Cholinergic activation of phasic
activity in the isolated bladder: possible evidence for M3- and
M2-dependent components of a motor/sensory system. BJU Int
2007, 100(3):668–678.
16. McCafferty GP, Misajet BA, Laping NJ, Edwards RM, Thorneloe KS: Enhanced
bladder capacity and reduced prostaglandin E2-mediated bladder
hyperactivity in EP3 receptor knockout mice. Am J Physiol Renal Physiol
2008, 295(2):F507–F514.
17. Borda E, Contreras-Ortiz N, Gutnisky R, Gimeno MF: In vitro effect of
acetylcholine and bethanechol on the contractions of the human
detrusor muscle. Influence of prostaglandins. Arch Int Pharmacodyn Ther
1982, 259(1):31–39.
18. Jeremy JY, Mikhailidis DP, Dandona P: Prostanoid synthesis by the rat urinary
bladder: evidence for stimulation through muscarine receptor-linked calcium
channels. Naunyn Schmiedebergs Arch Pharmacol 1986, 334(4):463–467.
19. Ishizuka O, Mattiasson A, Andersson KE: Prostaglandin E2-induced bladder
hyperactivity in normal, conscious rats: involvement of tachykinins?
J Urol 1995, 153(6):2034–2038.
20. de Jongh R, van Koeveringe GA, van Kerrebroeck PE, Markerink-van Ittersum
M, de Vente J, Gillespie JI: Damage to the bladder neck alters
autonomous activity and its sensitivity to cholinergic agonists. BJU Int
2007, 100(4):919–929.
21. Rahnama’i MS, van Koeveringe GA, Essers PB, de Wachter SG, de Vente J,
van Kerrebroeck PE, Gillespie JI: Prostaglandin receptor EP1 and EP2 site
in guinea pig bladder urothelium and lamina propria. J Urol 2010,
183(3):1241–1247.
22. Rahnama’i MS, de Wachter SG, van Koeveringe GA, van Kerrebroeck PE, de
Vente J, Gillespie JI: The relationship between prostaglandin E receptor 1
and cyclooxygenase I expression in guinea pig bladder interstitial cells:
proposition of a signal propagation system. J Urol 2011, 185(1):315–322.
23. Santoso AG, Lo WN, Liang W: Urothelium-dependent and
urothelium-independent detrusor contractility mediated by nitric
oxide synthase and cyclooxygenase inhibition. Neurourol Urodyn
2011, 30(4):619–625.
24. Tanaka I, Nagase K, Tanase K, Aoki Y, Akino H, Yokoyama O: Modulation of
stretch evoked adenosine triphosphate release from bladder epithelium
by prostaglandin E(2). J Urol 2011, 185(1):341–346.
25. Collins C, Klausner AP, Herrick B, Koo HP, Miner AS, Henderson SC, Ratz PH:
Potential for control of detrusor smooth muscle spontaneous rhythmic
contraction by cyclooxygenase products released by interstitial cells of
Cajal. J Cell Mol Med 2009, 13(9B):3236–3250.
26. Alkondon M, Ganguly DK: Release of prostaglandin E from the isolated
urinary bladder of the guinea-pig. Br J Pharmacol 1980, 69(4):573–577.
27. Yoshida M, Masunaga K, Satoji Y, Maeda Y, Nagata T, Inadome A: Basic and
clinical aspects of non-neuronal acetylcholine: expression of non-
neuronal acetylcholine in urothelium and its clinical significance.
J Pharmacol Sci 2008, 106(2):193–198.
28. Andersson KE: Words of wisdom. Re: spontaneous release of
acetylcholine from autonomic nerves in the bladder. Eur Urol 2010,
57(1):171–172.
29. Zagorodnyuk VP, Gregory S, Costa M, Brookes SJ, Tramontana M, Giuliani S,
Maggi CA: Spontaneous release of acetylcholine from autonomic nerves
in the bladder. Br J Pharmacol 2009, 157(4):607–619.
30. Koshita M, Hidaka K, Ueno H, Yamamoto Y, Suzuki H: Properties of
acetylcholine-induced hyperpolarization in smooth muscle cells of the
mouse mesenteric artery. J Smooth Muscle Res 2007, 43(6):219–227.
31. Finney SM, Andersson KE, Gillespie JI, Stewart LH: Antimuscarinic drugs in
detrusor overactivity and the overactive bladder syndrome: motor or
sensory actions? BJU Int 2006, 98(3):503–507.
Rahnama’i et al. BMC Urology 2013, 13:8 Page 9 of 9
http://www.biomedcentral.com/1471-2490/13/832. Andersson KE, Yoshida M: Antimuscarinics and the overactive detrusor–
which is the main mechanism of action? Eur Urol 2003, 43(1):1–5.
33. de Groat WC: The urothelium in overactive bladder: passive
bystander or active participant? Urology 2004, 64(6 Suppl 1):7–11.
34. Fry CH, Ikeda Y, Harvey R, Wu C, Sui GP: Control of bladder function by
peripheral nerves: avenues for novel drug targets. Urology 2004,
63(3 Suppl 1):24–31.
35. Gillespie JI: Inhibitory actions of calcitonin gene-related peptide and
capsaicin: evidence for local axonal reflexes in the bladder wall. BJU Int
2005, 95(1):149–156.
36. de Jongh R, Grol S, van Koeveringe GA, van Kerrebroeck PE, de Vente J,
Gillespie JI: The localisation of cyclo-oxygenase immuno-reactivity (COX
I-IR) to the urothelium and to interstitial cells in the bladder wall.
J Cell Mol Med 2008, 13(9B):3069–81.
37. Drake MJ, Harvey IJ, Gillespie JI, Van Duyl WA: Localized contractions in the
normal human bladder and in urinary urgency. BJU Int 2005,
95(7):1002–1005.
38. Kim JC, Park EY, Seo SI, Park YH, Hwang TK: Nerve growth factor and
prostaglandins in the urine of female patients with overactive bladder.
J Urol 2006, 175(5):1773–1776. discussion 1776.
39. Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK: Changes of urinary
nerve growth factor and prostaglandins in male patients with overactive
bladder symptom. Int J Urol 2005, 12(10):875–880.
40. Andersson KE: Bladder activation: afferent mechanisms. Urology 2002,
59(5 Suppl 1):43–50.
doi:10.1186/1471-2490-13-8
Cite this article as: Rahnama’i et al.: The effect of indomethacin on the
muscarinic induced contractions in the isolated normal guinea pig
urinary bladder. BMC Urology 2013 13:8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
